RxDoctor Payments Data

Mee Ooi

Psychiatric/Mental Health · San Antonio, TXNPI 1508476656

Payments from drug & device makers

$2,774in general payments, 2019–2025

Across 174 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$723
  • Alkermes, Inc.$327
  • Johnson & Johnson$325
  • AbbVie$325
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$265
  • Neurocrine Biosciences, Inc.$245
  • plus $564 from 6 others

What the payments were for

  • Food & beverage$2,56392%
  • Education$2118%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,774 in reported general payments places this provider in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$6,914
Medicare patients
54
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate108$363,080
Invega TrinzaPaliperidone Palmitate19$173,908
IngrezzaValbenazine Tosylate15$121,637
AristadaAripiprazole Lauroxil19$68,330
Abilify MaintenaAripiprazole25$64,233
VraylarCariprazine Hcl16$26,961
Clozapine91$12,078
Lurasidone Hcl44$10,699
TrintellixVortioxetine Hydrobromide20$10,652
Aripiprazole124$8,054
Olanzapine189$5,466
Hydroxyzine Hcl207$5,269
Paliperidone ErPaliperidone19$5,186
Divalproex Sodium ErDivalproex Sodium83$4,967
Buspirone Hcl196$2,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$325$536,989127 claims
Neurocrine Biosciences, Inc.Ingrezza$245$121,63715 claims
Alkermes, Inc.Aristada$327$68,33019 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$157$64,23325 claims
AbbVieVraylar$325$26,96116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →